PROGRESS AGAINST CANCER
Research improves survival and quality of life for people
around the world because it powers the development of
new and better ways to prevent, detect, diagnose, treat,
and cure some of the many diseases we call cancer.
Each clinical and legislative advance against cancer is the
culmination of many years of hard work by individuals
from all segments of the biomedical research community
(see sidebar on The Biomedical Research Community:
Powering Progress Together, p. 9).
Among the most prominent clinical advances against
cancer are the new medical products approved for use by
the U. S. Food and Drug Administration (FDA). Bringing
a new medical product from initial research discovery
• In the United States, the overall cancer death rate is decreasing, and the number of cancer
survivors is increasing.
• The reduction in the U.S. cancer death rate from 1991 to 2012 translates into
1. 7 million cancer deaths avoided.
• In 2016, 595,690 people are expected to die from some form of cancer in the United States,
making it the second most common cause of death.
• Not all segments of the U.S. population benefit equally from advances against cancer.
• The cost of cancer is enormous, both in the United States and globally.
CANCER IN 2016
In this section you will learn:
13 of 40 (32%)
novel drugs approved by the FDA’s
Center for Drug Evaluation and
Research from Aug. 1, 2015, to July
31, 2016, were for use in oncology.